Royal Bank Of Canada Nrx Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 05, 2024	BUY	$0.29 - $0.7 $36 - $87	125 New	125 $0
Q1 2024 May 15, 2024	SELL	$0.29 - $0.7 $43,524 - $105,058	-150,084 Reduced 99.92%	125 $0
Q4 2023 Feb 14, 2024	SELL	$0.26 - $0.47 $5,254 - $9,498	-20,210 Reduced 11.86%	150,209 $69,000
Q3 2023 Nov 14, 2023	SELL	$0.23 - $0.5 $187 - $407	-814 Reduced 0.48%	170,419 $44,000
Q2 2023 Aug 14, 2023	BUY	$0.46 - $0.89 $78,709 - $152,285	171,107 Added 135799.2%	171,233 $82,000
Q1 2023 May 15, 2023	SELL	$0.66 - $1.4 $1 - $2	-2 Reduced 1.56%	126 $0
Q4 2022 Feb 14, 2023	SELL	$0.79 - $9.19 $150 - $1,746	-190 Reduced 59.75%	128 $0
Q3 2022 Nov 14, 2022	SELL	$0.2 - $8.07 $41 - $1,654	-205 Reduced 39.2%	318 $0
Q2 2022 Aug 15, 2022	BUY	$0.51 - $2.42 $266 - $1,265	523 New	523 $0
Q3 2021 Nov 15, 2021	SELL	$8.52 - $24.77 $68,160 - $198,160	-8,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$11.62 - $44.5 $92,960 - $356,000	8,000 New	8,000 $93,000

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $81.2M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.